0 -2.38568588465804E-06 -2.38568588465804E-06 -0.000954274353876663 -0.000636182902584479 -0.00103379721669977 -0.00827037773359835 -0.00741948310139159
Sign Up Today X
Thanks for submitting the form.
Stockreport

Groundbreaking HIV Prevention Shots Begin In Africa [Barron's]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Barrons
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
in the drug's first public rollouts in Africa, which has the world's highest HIV burden. Lenacapavir, which is taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, making it functionally akin to a powerful vaccine. Advertisement - Scroll to Continue In South Africa, where one in five adults lives with HIV, a Wits University research unit oversaw the rollout as part of an initiative funded by Unitaid, the United Nations health agency. "The first individuals have begun using lenacapavir for HIV prevention in South Africa... making it among the first real-world use of the six-monthly injectable in low- and middle-income countries," Unitaid said in a statement. It did not specify how many people received the first doses of the drug, which cost $28,000 per person a year in the United States. A broader national rollout is expected next year. Neighbouring Zambia and Eswatini received 1,000 doses last month as part of a US programme [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Groundbreaking HIV Prevention Shots Begin In Africa [Barron's]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Barrons
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
in the drug's first public rollouts in Africa, which has the world's highest HIV burden. Lenacapavir, which is taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, making it functionally akin to a powerful vaccine. Advertisement - Scroll to Continue In South Africa, where one in five adults lives with HIV, a Wits University research unit oversaw the rollout as part of an initiative funded by Unitaid, the United Nations health agency. "The first individuals have begun using lenacapavir for HIV prevention in South Africa... making it among the first real-world use of the six-monthly injectable in low- and middle-income countries," Unitaid said in a statement. It did not specify how many people received the first doses of the drug, which cost $28,000 per person a year in the United States. A broader national rollout is expected next year. Neighbouring Zambia and Eswatini received 1,000 doses last month as part of a US programme [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS